Literature DB >> 15821003

C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study.

David E Laaksonen1, Leo Niskanen, Kristiina Nyyssönen, Kari Punnonen, Tomi-Pekka Tuomainen, Jukka T Salonen.   

Abstract

AIMS: Cut-offs for C-reactive protein concentrations have been recommended for risk stratification, but little is known about how these cut-offs predict cardiovascular risk in population-based cohorts. We therefore assessed the association of C-reactive protein levels with cardiovascular mortality in a population-based cohort of 2321 middle-aged men stratified by the presence of cardiovascular disease (CVD) at baseline. METHODS AND
RESULTS: C-reactive protein concentrations were categorized according to current recommendations (1 and 3 mg/L). During the 15 year follow-up, 77 men without CVD and 121 men with CVD at baseline died of CVD. In men without CVD at baseline (n=1476), age-adjusted cardiovascular mortality was 4.1-fold higher (95% CI 2.1-8.2) for C-reactive protein levels between 3.0 and 9.9 mg/L at baseline than for C-reactive protein levels <1.0 mg/L. In men with CVD at baseline (n=845), the corresponding age-adjusted cardiovascular mortality was 3.3-fold higher (95% CI 2.0-5.3). Adjustment for conventional CVD risk factors attenuated the risk somewhat. Further adjustment for dietary and lifestyle factors and factors related to insulin resistance did not affect the association. Classification of C-reactive protein by tertiles gave qualitatively similar results, but identified twice as many men at high risk. C-reactive protein levels also predicted overall mortality.
CONCLUSION: Currently, recommended cut-offs for C-reactive protein levels identify men at risk for cardiovascular and overall death independently of conventional and other risk factors in a population-based sample of middle-aged men with and without CVD at baseline. Lower cut-offs may better identify men at high risk for cardiovascular death, but improvement of current recommendations will require standardization of C-reactive protein assays.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15821003     DOI: 10.1093/eurheartj/ehi237

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  25 in total

1.  Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes.

Authors:  Emily G Kurtz; Paul M Ridker; Lynda M Rose; Nancy R Cook; Brendan M Everett; Julie E Buring; Kathryn M Rexrode
Journal:  Menopause       Date:  2011-01       Impact factor: 2.953

2.  Dyslipidaemia as a predictor of hypertension in middle-aged men.

Authors:  David E Laaksonen; Leo Niskanen; Kristiina Nyyssönen; Timo A Lakka; Jari A Laukkanen; Jukka T Salonen
Journal:  Eur Heart J       Date:  2008-02-28       Impact factor: 29.983

3.  Risk for metabolic syndrome predisposes to alterations in the thalamic metabolism.

Authors:  Outi Heikkilä; Nina Lundbom; Marjut Timonen; Per-Henrik Groop; Sami Heikkinen; Sari Mäkimattila
Journal:  Metab Brain Dis       Date:  2008-07-22       Impact factor: 3.584

Review 4.  The use of high-sensitivity assays for C-reactive protein in clinical practice.

Authors:  Kiran Musunuru; Brian G Kral; Roger S Blumenthal; Valentin Fuster; Catherine Y Campbell; Ty J Gluckman; Richard A Lange; Eric J Topol; James T Willerson; Milind Y Desai; Michael H Davidson; Samia Mora
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-08-19

5.  Insulin resistance and systemic inflammation, but not metabolic syndrome phenotype, predict 9 years mortality in older adults.

Authors:  Giovanni Zuliani; Mario Luca Morieri; Stefano Volpato; Marcello Maggio; Antonio Cherubini; Daniela Francesconi; Stefania Bandinelli; Giuseppe Paolisso; Jack M Guralnik; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2014-06-10       Impact factor: 5.162

6.  Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy.

Authors:  Walckiria G Romero; Fabrício B Da Silva; Mariana V Borgo; Nazaré S Bissoli; Sonia A Gouvêa; Gláucia R Abreu
Journal:  Oncologist       Date:  2012-04-04

7.  Psychological distress and C-reactive protein: do health behaviours and pathophysiological factors modify the association?

Authors:  Pekka Johannes Puustinen; Hannu Koponen; Hannu Kautiainen; Pekka Mäntyselkä; Mauno Vanhala
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-08-14       Impact factor: 5.270

8.  Usefulness of C-reactive protein as a marker for prediction of future coronary events in the asian Indian population: Indian atherosclerosis research study.

Authors:  Veena S Rao; Natesha B Kadarinarasimhiah; Shibu John; Sridhara Hebbagodi; Jayashree Shanker; Vijay V Kakkar
Journal:  Int J Vasc Med       Date:  2010-06-28

Review 9.  Obesity, inflammation, and atherosclerosis.

Authors:  Viviane Z Rocha; Peter Libby
Journal:  Nat Rev Cardiol       Date:  2009-04-28       Impact factor: 32.419

10.  The Correlation between High-Sensitivity C-Reactive Protein, Matrix Metallopeptidase 9, and Traditional Chinese Medicine Syndrome in Patients with Hypertension.

Authors:  Aiming Wu; Dongmei Zhang; Yonghong Gao; Lixia Lou; Haiyan Zhu; Limin Chai; Xiying Lv; Yikun Sun; Lingqun Zhu; Shuoren Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.